Holen Sie sich die Stockscreener-App
3.92
1.81%
0.06
Schlusskurs vom Vortag:
$3.86
Offen:
$3.87
24-Stunden-Volumen:
2,375
Relative Volume:
0.10
Marktkapitalisierung:
$7.45M
Einnahmen:
$6.50M
Nettoeinkommen (Verlust:
$-29.58M
KGV:
-0.24
EPS:
-16.3362
Netto-Cashflow:
$-34.58M
1W Leistung:
+2.34%
1M Leistung:
-2.96%
6M Leistung:
-4.61%
1J Leistung:
-21.87%
1-Tages-Spanne:
$3.8668
$3.92
1-Wochen-Bereich:
$3.53
$3.9999
52-Wochen-Spanne:
$3.13
$7.1999
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Firmenname
Bolt Biotherapeutics Inc
Sektor
Branche
Telefon
650-665-9295
Adresse
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
3.8668 | 7.44M | 6.50M | -29.58M | -34.58M | -16.34 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.05 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.68 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.07 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | Eingeleitet | Guggenheim | Buy |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Bolt Biotherapeutics Inc Aktie (BOLT) Neueste Nachrichten
BOLT Q2 2026 Earnings: Wider-than-Expected Per-Share Loss of -$4.57 Highlights Cost PressuresEBITDA Margin Trends - vinanet.vn
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Barchart.com
BOLT Q2 2026 Earnings: Widened Loss of -$4.57 Per Share Misses Consensus by 32.3%Return On Assets - vinanet.vn
Bolt Biotherapeutics . Stock Price Forecast. Should You Buy BOLT? - StockInvest.us
Bolt Biotherapeutics (BOLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bolt (BOLT) Levels: Records a 2.60% Increase to $3.26 in the Current Update; Price Context: the Near-Term Reference Band Stretches From $3.10 to $3.42 in the Current UpdateTrend Following Picks - vinanet.vn
Bolt (BOLT) Quarterly Figures: The EPS Result Is Below Expectation; Price Reaction: Shares Fall 0.72%Buyback Announcement Report - vinanet.vn
Bolt Biotherapeutics (BOLT) Gains 4.36% as Shares Test Key Technical LevelsLarge Cap Trends - Vinanet
Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics - Stock Titan
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BOLT Looks 49.0% Undervalued on GF Value™ Despite Clinical-Stage Challenges - GuruFocus
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot - KHOU
Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity - TradingView
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary - TradingView
BOLT: BDC-4182 trial progresses as cash runway extends into Q1 2027 amid lower Q2 expenses - TradingView
Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M - Stock Titan
Press Release: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics (BOLT) Advances 4.65% as Buyers Defend Key SupportHigh Volume Node - vinanet.vn
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BOLT Q2'26 Earnings: revenue estimate is 500.00K USD - TradingView
Bolt Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Bolt Biotherapeutics Inc (BOLT) Cash Flow - TradingKey
BOLT|Bolt Biotherapeutics Inc|Price:3.830|Chg%:+0.110 - TradingKey
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss Amid Clinical Development ProgressAnalyst Consensus Shift - dars.gov.et
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss as Development Stage Company Reports No RevenueSegment Revenue Breakdown - vinanet.vn
Bolt Biotherapeutics (BOLT) Climbs 7% as Support HoldsAdvance Decline Line - vinanet.vn
Bolt Biotherapeutics (BOLT) Gains Momentum: Stock Rises 1.82% Amid Potential Biotech RallyZigzag Correction - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
A419U9 Forecast — Price Target — Prediction for 2027 - TradingView
BOLT Forecast — Price Target — Prediction for 2027 - TradingView
Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0) - TradingView
Enterprise value to revenue forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Revenue per share of Bolt Biotherapeutics, Inc. – FWB:6LP0 - TradingView
6LP0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics (BOLT) Slides 5% in Heavy Trading as Key Support Level ApproachesVOLD Alert - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bolt Biotherapeutics Inc (BOLT) Institutional Confidence - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Large EPS Miss Reflects Continued R&D InvestmentEPS Growth Rate - newsline.com
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price - Stock Titan
Finanzdaten der Bolt Biotherapeutics Inc-Aktie (BOLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):